Valuation : Thiogenesis Therapeutics, Corp.

Market Cap 34.99M 25.29M 21.76M 20.48M 18.7M 2.39B 35.09M 242M 93.89M 1.23B 94.97M 92.9M 3.95B P/E 2024
-8.65x
P/E 2025 -4.25x
Enterprise Value 33.37M 24.12M 20.76M 19.53M 17.84M 2.28B 33.46M 231M 89.55M 1.17B 90.58M 88.61M 3.76B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.91%
Yield 2024 *
-
Yield 2025 -
1 day-1.96%
1 week-1.96%
Current month-7.41%
1 month-7.41%
3 months-16.67%
Current year-23.08%
1 week 0.5
Extreme 0.5
0.55
1 month 0.5
Extreme 0.5
0.58
Current year 0.44
Extreme 0.44
0.66
1 year 0.44
Extreme 0.44
0.81
3 years 0.44
Extreme 0.44
1.06
5 years 0.38
Extreme 0.375
1.06
10 years 0.38
Extreme 0.375
1.06
Manager TitleAgeSince
Chief Executive Officer 75 31/03/2022
Chief Executive Officer 60 -
Director TitleAgeSince
Chairman 73 31/03/2022
Director/Board Member 75 31/03/2022
Director/Board Member 60 03/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
1/6/26 Sell

Director

150,000 0.2894%
11/9/25 Option

Director

75,000 0.1702%
1/8/25 Sell

Director

64,000 0.1453%
Change 5-day change 1-year change 3-year change Capi.($)
-1.96%-1.96%-35.90%-29.58% 25.29M
-2.54%-2.84%-1.90%+14.52% 48.93B
-0.40%+1.03%+439.20%+499.20% 45.01B
-1.42%+2.30%+45.46%+19.36% 44.07B
-1.22%-2.31%+12.40%+71.48% 40.73B
+0.53%-1.36%+16.04%+48.23% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+22.59%+116.19% 16.5B
-1.01%+0.50%+15.83%+27.98% 14.67B
-1.65%-1.03%+77.75%+37.63% 13.77B
Average -1.02%+0.48%+65.72%+89.45% 27.5B
Weighted average by Cap. -1.03%+0.11%+94.85%+122.10%

Financials

2024 2025
Net sales - -
Net income -3.15M -2.27M -1.96M -1.84M -1.68M -215M -3.15M -21.75M -8.44M -110M -8.54M -8.35M -355M -7.43M -5.37M -4.62M -4.35M -3.97M -507M -7.45M -51.35M -19.93M -260M -20.16M -19.72M -838M
Net Debt -3.85M -2.78M -2.39M -2.25M -2.06M -263M -3.86M -26.61M -10.32M -135M -10.44M -10.22M -434M -1.62M -1.17M -1.01M -946K -864K -110M -1.62M -11.17M -4.34M -56.58M -4.39M -4.29M -182M
Logo Thiogenesis Therapeutics, Corp.
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102’s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.
Employees
-
Date Price Change Volume
04/09/26 CAD 0.5000 -1.96% 11,500
03/09/26 CAD 0.5100 -1.92% 156,000
02/09/26 CAD 0.5200 -3.70% 1,000

Net sales - Rate of surprise